Drug search by name

Fibrinogen Concentrate (Human) and Thrombotic events

Result of checking the interaction of drug Fibrinogen Concentrate (Human) and disease Thrombotic events for safety when used together.

Check result:

Fibrinogen Concentrate (Human) <> Thrombotic events

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Thrombotic events have been reported in patients receiving human fibrinogen concentrate. Treatment with human fibrinogen concentrate has been associated with risk of thrombosis at target fibrinogen levels that were less than 150 mg/dL, and the risk may be greater when the target fibrinogen plasma level is 150 mg/dL. Weigh the benefits of fibrinogen administration versus the risks of thrombosis. Patients receiving fibrinogen should be monitored for signs and symptoms of thrombosis. Inform patients that blood clots with or without consequent obstruction of blood flow may occur and that any symptoms of blood clots (unexplained chest and/or leg pain or swelling of the legs or arms, coughing up blood, shortness of breath, increased rate of breathing or unexplained symptoms related to the nervous system such as stroke or weakness) should be reported to their physician immediately.

Fibrinogen Concentrate (Human)

Generic Name: fibrinogen

Brand Name: RiaSTAP

Synonyms: Fibrinogen

What is Fibrinogen Concentrate (Human)?